A multicentric observational study assessing the safety and seroconversion rates of mRNA and inactivated vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
Latest Information Update: 13 Dec 2021
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 13 Dec 2021 New trial record
- 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis